FDA
-
-
-
-
-
-
-
InVivo Therapeutics Announces Pricing of $15.0 Million Public Offering
-
-
-
-
-
-
-
Invivo Therapeutics (NVIV) Announces Proposed Public Offering of Common Stock
-
-
-
-
-
-
-
InVivo Therapeutics Announces Presentation of Twelve-Month Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury
-
-
-
-
-
-
-
InVivo Therapeutics Announces Complete 12-Month Data from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury
-
-
-
-
-
-
-
InVivo Therapeutics Announces Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”) Findings
-
-
-
-
-
-
-
Invivo Therapeutics (NVIV) Provides Latest Results from INSPIRE and Provides Update on Proposed Clinical Path Forward
-
-
-
-
-
-
-
InVivo Therapeutics Provides Business Update and Reports 2017 Second Quarter Financial Results
-
323,759 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

